Latest News and Press Releases

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable...

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet...

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to...

Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around...

Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first...

ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to...

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients,...

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a...